Next Article in Journal
Morphine Accumulates in the Retina Following Chronic Systemic Administration
Next Article in Special Issue
Covalent Inhibition of the Human 20S Proteasome with Homobelactosin C Inquired by QM/MM Studies
Previous Article in Journal
Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
Previous Article in Special Issue
Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline–Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 5
10.3390/ph15050526
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceuticals 2022, 15(3), 384.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Alfei, S.; Zuccari, G. Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 2022, 15, 384

by
Silvana Alfei
* and
Guendalina Zuccari
Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano, 16148 Genoa, Italy
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(5), 526; https://doi.org/10.3390/ph15050526
Submission received: 12 April 2022 / Accepted: 13 April 2022 / Published: 25 April 2022
(This article belongs to the Special Issue Design of Enzyme Inhibitors as Potential Drugs 2022)
Browse Figures
Versions Notes

Error in Table

In the original publication [1], there were two mistakes in Table 3 as published. In the chemical structure of ANT-3310 (column 2, row 16) the NO bond was not clearly visible, and in the chemical structure of ANT-2681 (column 2, row 22), an amide functionality, was linked to the thiazole ring in place of an acid one. The corrected Structures of ANT-3310 and ANT-2681 appear below.
Pharmaceuticals 15 00526 i001
ANT-3310
Pharmaceuticals 15 00526 i002
ANT-2681

Error in Schemes

In the original publication, there was a mistake in Scheme 16 as published. In the first three chemical structures of Scheme 16, a BnO ester functionality was reported in the place of an EtO one. The corrected Scheme 16 appears below.
In the original publication, there was a mistake in Scheme 23 as published. In the final structure of ANT-2681, the PMB protecting group should not have been present. The corrected Scheme 23 appears below.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.
Pharmaceuticals 15 00526 sch001 550
Scheme 16. Synthesis of ANT-3310 (C6H9 FN2O5S, MW = 240.2), IUPAC name, (2R,5R)-2-fluoro-7-oxo-1,6-diazabicyclo [3.2.1] octan-6-yl hydrogen sulphate.
Scheme 16. Synthesis of ANT-3310 (C6H9 FN2O5S, MW = 240.2), IUPAC name, (2R,5R)-2-fluoro-7-oxo-1,6-diazabicyclo [3.2.1] octan-6-yl hydrogen sulphate.
Pharmaceuticals 15 00526 sch001
Pharmaceuticals 15 00526 sch002 550
Scheme 23. Synthesis of ANT-2681 ANT-2681 (C12H12F2N8O4S2, MW = 434.4), IUPAC name: 5-((4-(2-Carbamimidoylhydrazine-1-carboxamido)-3,5-difluorophenyl) sulphonamide) thiazole-4-carboxamide.
Scheme 23. Synthesis of ANT-2681 ANT-2681 (C12H12F2N8O4S2, MW = 434.4), IUPAC name: 5-((4-(2-Carbamimidoylhydrazine-1-carboxamido)-3,5-difluorophenyl) sulphonamide) thiazole-4-carboxamide.
Pharmaceuticals 15 00526 sch002

Reference

  1. Alfei, S.; Zuccari, G. Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 2022, 15, 384. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Alfei, S.; Zuccari, G. Correction: Alfei, S.; Zuccari, G. Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 2022, 15, 384. Pharmaceuticals 2022, 15, 526. https://doi.org/10.3390/ph15050526

AMA Style

Alfei S, Zuccari G. Correction: Alfei, S.; Zuccari, G. Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 2022, 15, 384. Pharmaceuticals. 2022; 15(5):526. https://doi.org/10.3390/ph15050526

Chicago/Turabian Style

Alfei, Silvana, and Guendalina Zuccari. 2022. "Correction: Alfei, S.; Zuccari, G. Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 2022, 15, 384" Pharmaceuticals 15, no. 5: 526. https://doi.org/10.3390/ph15050526

APA Style

Alfei, S., & Zuccari, G. (2022). Correction: Alfei, S.; Zuccari, G. Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 2022, 15, 384. Pharmaceuticals, 15(5), 526. https://doi.org/10.3390/ph15050526

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop